Shares in Bellerophon Therapeutics (NSDQ:BLPH) fell today even though the company beat expectations on Wall Street with its second quarter results.
The Warren, N.J.-based company posted a net loss of -$3.9 million with no sales for the 3 months ended June 30, for bottom-line growth of 23% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.